ArticleNature immunology2026
ZFP148 is a transcriptional repressor of cytolytic effector CD8
Abstract read
In one paragraph
Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Tong XiaoPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Xingyu ChenDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9284-4950
No-Joon SongPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Ryan J BrownDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Anjun MaPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-6269-398X
Jay K MandulaPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Amir YousifPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Yi WangPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Minh Quynh May LePelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Jianying LiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Fengxia GaoPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Bella WeaverPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Heng-Yi ChenPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-9283-6144
Fang-Yun LayPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Debasish SundiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Maria VelegrakiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-3062-9777
Payton WeltgePelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Juanita L MerchantUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Mark P RubinsteinPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Kenneth J OestreichPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3004-072X
Chan-Wang Jerry LioPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Hazem E GhoneimPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-9816-4286
Xue LiDepartments of Medicine and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Dan TheodorescuUniversity of Arizona Cancer Center, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-8708-8206
Gang XinPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.
Qin MaPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3264-8392
Weiguo CuiDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-1562-9218
Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Center and Solove Research Institute, Columbus, OH, USA. Zihai.li@osumc.edu.ORCID http://orcid.org/0000-0003-4603-927X
Funding
The Role of the Y Chromosome in Bladder Tumor Development, Growth And ProgressionP01CA278732 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Hany Abdel-Malek Abdel-Hafiz · 2023 to 2026
$10.7MSexual Dimorphism in Bladder CancerR01CA267108 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Xue Sean Li · 2022 to 2026
$2.9MMolecular Mechanism of TET-mediated Gene RegulationR35GM151110 · NIGMS · OHIO STATE UNIVERSITY · PI Jerry Chan-Wang Lio · 2023 to 2026
$1.5MTargeting GPR84 to Overcome Macrophage Mediated Resistance to ImmunotherapyR01CA269984 · NCI · OHIO STATE UNIVERSITY · PI Gang Xin · 2023 to 2026
$1.4MNCI NIH HHS P01 CA278732NCI NIH HHS R01 CA267108NCI NIH HHS R01 CA269984NIGMS NIH HHS R35 GM151110
Abstract
Progenitor CD8
Indexed as
CD8-Positive T-LymphocytesCell DifferentiationDNA-Binding ProteinsT-Lymphocytes, CytotoxicTranscription FactorsAnimalsHumansKruppel-Like Transcription FactorsLymphocytes, Tumor-InfiltratingLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceMice, Inbred C57BLMice, KnockoutProgrammed Cell Death 1 ReceptorT-Cell ExhaustionDNA-Binding ProteinsKlf2 protein, mouseKruppel-Like Transcription FactorsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.